Cargando…

In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity

Matrix metalloproteinase-2 (MMP2) is important in tumorigenesis, angiogenesis and tumor invasion. In this study, we investigated if the Cy5-tagged small immuno protein targeting the catalytic domain of human MMP2 (aMMP2-SIP) detects MMP2 in tumors non-invasively. For this purpose, we generated MMP2...

Descripción completa

Detalles Bibliográficos
Autores principales: Panth, Kranthi Marella, van den Beucken, Twan, Biemans, Rianne, Lieuwes, Natasja G., Weber, Marcel, Losen, Mario, Yaromina, Ala, Dubois, Ludwig J., Lambin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770595/
https://www.ncbi.nlm.nih.gov/pubmed/26923459
http://dx.doi.org/10.1038/srep22198
_version_ 1782418291580469248
author Panth, Kranthi Marella
van den Beucken, Twan
Biemans, Rianne
Lieuwes, Natasja G.
Weber, Marcel
Losen, Mario
Yaromina, Ala
Dubois, Ludwig J.
Lambin, Philippe
author_facet Panth, Kranthi Marella
van den Beucken, Twan
Biemans, Rianne
Lieuwes, Natasja G.
Weber, Marcel
Losen, Mario
Yaromina, Ala
Dubois, Ludwig J.
Lambin, Philippe
author_sort Panth, Kranthi Marella
collection PubMed
description Matrix metalloproteinase-2 (MMP2) is important in tumorigenesis, angiogenesis and tumor invasion. In this study, we investigated if the Cy5-tagged small immuno protein targeting the catalytic domain of human MMP2 (aMMP2-SIP) detects MMP2 in tumors non-invasively. For this purpose, we generated MMP2 expressing (empty vector EV) and knock-down (KD) HT1080, U373 and U87 cells, which were injected subcutaneously in the lateral flank of NMRI-nu mice. Optical imaging (Optix MX2) performed at 0.5, 2, 4, 8, 24 and 48 hour post injection (h.p.i.) of Cy5 tagged aMMP2-SIP, indicated significantly lower tumor to background ratios at both 24 (P = 0.0090) and 48 h.p.i. (P < 0.0001) for the U87 MMP2-KD compared to control tumors. No differences were found for HT1080 and U373 models. U87 MMP2-KD tumors had significantly lower MMP2 activity (P < 0.0001) than EV tumors as determined by gelatin zymography in tumor sections and lysates, while no differences were observed between EV and MMP2-KD in HT1080 and U373. In line with these data, only U87 MMP2-KD tumors had a reduced tumor growth compared to control tumors (P = 0.0053). aMMP2-SIP uptake correlates with MMP2 activity and might therefore be a potential non-invasive imaging biomarker for the evaluation of MMP2 activity in tumors.
format Online
Article
Text
id pubmed-4770595
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47705952016-03-07 In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity Panth, Kranthi Marella van den Beucken, Twan Biemans, Rianne Lieuwes, Natasja G. Weber, Marcel Losen, Mario Yaromina, Ala Dubois, Ludwig J. Lambin, Philippe Sci Rep Article Matrix metalloproteinase-2 (MMP2) is important in tumorigenesis, angiogenesis and tumor invasion. In this study, we investigated if the Cy5-tagged small immuno protein targeting the catalytic domain of human MMP2 (aMMP2-SIP) detects MMP2 in tumors non-invasively. For this purpose, we generated MMP2 expressing (empty vector EV) and knock-down (KD) HT1080, U373 and U87 cells, which were injected subcutaneously in the lateral flank of NMRI-nu mice. Optical imaging (Optix MX2) performed at 0.5, 2, 4, 8, 24 and 48 hour post injection (h.p.i.) of Cy5 tagged aMMP2-SIP, indicated significantly lower tumor to background ratios at both 24 (P = 0.0090) and 48 h.p.i. (P < 0.0001) for the U87 MMP2-KD compared to control tumors. No differences were found for HT1080 and U373 models. U87 MMP2-KD tumors had significantly lower MMP2 activity (P < 0.0001) than EV tumors as determined by gelatin zymography in tumor sections and lysates, while no differences were observed between EV and MMP2-KD in HT1080 and U373. In line with these data, only U87 MMP2-KD tumors had a reduced tumor growth compared to control tumors (P = 0.0053). aMMP2-SIP uptake correlates with MMP2 activity and might therefore be a potential non-invasive imaging biomarker for the evaluation of MMP2 activity in tumors. Nature Publishing Group 2016-02-29 /pmc/articles/PMC4770595/ /pubmed/26923459 http://dx.doi.org/10.1038/srep22198 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Panth, Kranthi Marella
van den Beucken, Twan
Biemans, Rianne
Lieuwes, Natasja G.
Weber, Marcel
Losen, Mario
Yaromina, Ala
Dubois, Ludwig J.
Lambin, Philippe
In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
title In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
title_full In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
title_fullStr In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
title_full_unstemmed In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
title_short In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
title_sort in vivo optical imaging of mmp2 immuno protein antibody: tumor uptake is associated with mmp2 activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770595/
https://www.ncbi.nlm.nih.gov/pubmed/26923459
http://dx.doi.org/10.1038/srep22198
work_keys_str_mv AT panthkranthimarella invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity
AT vandenbeuckentwan invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity
AT biemansrianne invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity
AT lieuwesnatasjag invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity
AT webermarcel invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity
AT losenmario invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity
AT yarominaala invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity
AT duboisludwigj invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity
AT lambinphilippe invivoopticalimagingofmmp2immunoproteinantibodytumoruptakeisassociatedwithmmp2activity